Lifex Biolabs
Preclinical biotechnology company focused on discovery and development of small-molecule therapeutics for neurodegenerative diseases, metabolic disorders, and oncology. Uses structure-based and fragment-based approaches (including NMR-based screening) to identify targets and optimize small-molecule candidates. Maintains a pipeline of preclinical programs at discovery and lead-optimization stages.
Industries
Nr. of Employees
small (1-50)
Products
LF101 — CNS small-molecule discovery (1st generation)
Preclinical small-molecule program for central nervous system disease (first-generation program); listed at discovery stage on company pipeline.
LF102 — Parkinson's disease small-molecule (oral)
Preclinical small-molecule program targeting Parkinson's disease (first-generation, oral modality) described as in lead-optimization.
LF103 — Parkinson's disease small-molecule (intranasal)
Preclinical second-generation Parkinson's program using an intranasal small-molecule modality; described as in lead-optimization.
LF501 — VRK1-targeted oncology small-molecule (oral)
Preclinical small-molecule program targeting VRK1-positive solid tumors (breast and lung), described as oral modality in lead-optimization.
LF601 — Type 2 diabetes small-molecule (oral)
Preclinical small-molecule program for type 2 diabetes (oral modality) listed at discovery stage.
LF701 — Dementia with Lewy bodies small-molecule (oral)
Preclinical small-molecule program targeting dementia with Lewy bodies (oral modality) listed at discovery stage.
LF101 — CNS small-molecule discovery (1st generation)
Preclinical small-molecule program for central nervous system disease (first-generation program); listed at discovery stage on company pipeline.
LF102 — Parkinson's disease small-molecule (oral)
Preclinical small-molecule program targeting Parkinson's disease (first-generation, oral modality) described as in lead-optimization.
LF103 — Parkinson's disease small-molecule (intranasal)
Preclinical second-generation Parkinson's program using an intranasal small-molecule modality; described as in lead-optimization.
LF501 — VRK1-targeted oncology small-molecule (oral)
Preclinical small-molecule program targeting VRK1-positive solid tumors (breast and lung), described as oral modality in lead-optimization.
LF601 — Type 2 diabetes small-molecule (oral)
Preclinical small-molecule program for type 2 diabetes (oral modality) listed at discovery stage.
LF701 — Dementia with Lewy bodies small-molecule (oral)
Preclinical small-molecule program targeting dementia with Lewy bodies (oral modality) listed at discovery stage.
Expertise Areas
- Structure-based drug discovery
- Fragment-based screening (NMR)
- Small-molecule medicinal chemistry and lead optimization
- Preclinical program development
Key Technologies
- NMR spectroscopy
- Fragment-based screening
- Structure-based design
- Small-molecule medicinal chemistry
News & Updates
News release referenced on company site reporting a study linking a molecular pair to potential Parkinson's disease treatment.
Article referenced on company site summarizing research on PGE1/PGA1 effects on dopamine and neuronal protection.
News release referenced on company site about research indicating existing antimalarial drugs could have effects relevant to Parkinson's disease.
Reference to a published study on modulation of the Nurr1 nuclear receptor by prostaglandin-related compounds.
News release referenced on company site reporting a study linking a molecular pair to potential Parkinson's disease treatment.
Article referenced on company site summarizing research on PGE1/PGA1 effects on dopamine and neuronal protection.
News release referenced on company site about research indicating existing antimalarial drugs could have effects relevant to Parkinson's disease.
Reference to a published study on modulation of the Nurr1 nuclear receptor by prostaglandin-related compounds.